Quectel response to FCC about IoT module security
Quectel Wireless Solutions, a global IoT solutions provider, today commented on the recent letter and response being published by the FCC and the Select Committee of the US Congress questioning if Quectel’s IoT modules represent a potential security risk.
“We welcome the opportunity to work with the FCC and other U.S. government entities to demonstrate our compliance and best practice device security approach, says Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “We are committed to contributing to the advancement of a smarter world by delivering best-in-class and secure products. This commitment is evidenced by our extensive device OEM customer base and our constant focus on providing our customers with the best and most secure modules in the industry.”
The Select Committee to the US Congress’ letter to the FCC had several misconceptions about how Quectel modules work. Quectel’s clarification regarding the statements made in the letter is as follows.
Committee letter: “Connectivity modules are typically controlled remotely and are the necessary link between the device and the internet.”
Quectel’s U.S. customers or their customers’ third-party suppliers/service providers handle device and data management exclusively. Firmware updates are managed and controlled by the device original equipment manufacturer (OEM), not Quectel.
Committee letter: “Serving as the link between the device and the internet, these modules have the capacity both to brick the device and to access the data flowing from the device to the web server that runs each device”
The control of Quectel modules resides with the microcontroller unit (MCU) or central processing unit (CPU) embedded within the customer's device. Quectel itself does not possess any control; instead, this authority rests solely with the OEM – the entity responsible for developing the device. Remote management of the device is achievable solely through the OEM's device management platform. A notable instance of this, referred to in the letter, is the widely covered case involving John Deere agricultural equipment, where just the OEM typically can disable the equipment by accessing and shutting down its own MCU’s controlling the machine.
Committee letter: “As a result, if the CCP can control the module, it may be able to effectively exfiltrate data or shut down the IoT device.”
Once Quectel modules leave the factory and are delivered to its customers, Quectel customers own the data, and Quectel has no access to any of the data collected. The ownership, control, storage, and modification of the data generated by IoT devices within the market firmly rest with the OEM device makers and its customers. Even in the rare cases outside of the U.S. where Quectel resells the connectivity service of a wireless carrier, Quectel does not have access to the device data.
Committee letter: “This raises particularly grave concerns in the context of critical infrastructure and any type of sensitive data.”
Applications that require high security, such as critical infrastructure, typically use private access point names (APNs) and other methods which strictly control and monitor network access. This can be used to control and monitor any data flowing to and from the device. Critical infrastructure is meticulously fashioned with a multi-tiered security approach defined and implemented solely by the device OEM, not Quectel.
The cellular industry is heavily regulated and requires intensive testing and accreditation. Carrier and regulatory certifications are executed by trusted third-party labs and carrier labs, assuring that the module complies with strict technical requirements. The Quectel modules have obtained certifications from the FCC, PCS Type Certification Review Board (PTCRB) and major carriers throughout the world, which underlines Quectel’s commitment to meeting rigorous industry standards.
In addition to cellular modules, Quectel also provides Wi-Fi, Bluetooth and GNSS modules and antennas. As a GSMA member, Quectel and its carrier partners comply with all cellular industry regulations and applicable standards to ensure that end customer data is securely transmitted between customer device and mobile network operator. Quectel does not have access to ANY of the device data.
Quectel is committed to delivering high-quality, best-in-class, secure modules and go above and beyond industry standard practices by conducting independent third-party cyber security audits. More recently Quectel also retained the security firm Finite State, which is auditing and penetration testing the security of its modules through rigorous security testing, improved software supply chain visibility, and comprehensive software risk management. Quectel is also participating in the formulation of new industry security certification standards, such as the CTIA Cybersecurity Certification Working Group and pursuing additional cyber security certifications from various U.S. entities as new standards are formulated and adopted.
Qualcomm manufactures the chipsets and software platforms that are at the core of the Quectel modules. “Our Qualcomm partnership underlines the importance we place on working with well-trusted and secure partners from across the ecosystem to deliver high-quality solutions globally,” Mr. Muhrer continues. “Quectel's impact on the global IoT industry is profound. We supplied millions of cellular modules to support the distribution of Covid-19 vaccines for leading U.S. and global organizations including Pfizer, Johnson & Johnson, and other leading suppliers of vaccines. This underscores our commitment to playing a pivotal role in critical global initiatives.”
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X (formerly known as Twitter).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230907525548/en/
Contact information
Media contact: media@quectel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
